The U.K.’s national health spending watchdog will reevaluate its decision to exclude the use of two Alzheimer’s drugs ...

Turning Tides, a DTC campaign from Biogen and Supernus, uses storm-at-sea imagery and a streaming-first media plan to connect with new parents and spotlight the first oral treatment for postpartum ...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus ...

Biogen recently reported fourth-quarter and full-year 2025 results showing quarterly sales of US$521.2 million and revenue of US$2.28 billion, but a quarterly net loss of US$48.9 million contrasted ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Lupus R&D has been slow to progress with only two biologics ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA, ...

Biogen (NasdaqGS:BIIB) has appointed Dr. Maria C. Freire as Chair of its Board of Directors. Dr. Freire brings experience in biomedical research, drug development, and public private partnerships. The ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its chief executive officer said in an interview. Lilly’s drug, Kisunla, launched ...

Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: ...